Home・Akcijų sąrašas・Pfizer

Pfizer

Uždarymo kaina

SektoriusSveikatos priežiūra

27.26 1.3

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

26.86

Max

27.37

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-2.9B -238M
Pardavimai	583M 15B
P/E Sektoriaus vid.	35.355 57.371
Pelnas, tenkantis vienai akcijai	0.77
Dividendų pajamingumas	6.42
Pelno marža	-1.583
Darbuotojai	75,000
EBITDA	-3.8B 1.2B

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+6.1% upside

Dividendai
By Acuity
Dividendų pajamingumas Sektoriaus vid.	6.42% 2.23%
Kitas uždarbis	2026-11-03
Kitas dividendų mokėjimo data	2026-09-01
Kita Ex Dividend data	2026-11-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	10B 153B
Ankstesnė atidarymo kaina	25.96
Ankstesnė uždarymo kaina	27.26

Naujienos nuotaikos

By Acuity

35%

65%

128 / 340 reitingas Healthcare

Pfizer Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-08-18 19:16; UTC

Social Media

Event

Pfizer reported second-quarter adjusted EPS of $0.77, exceeding estimates, and raised its sales outlook for fiscal year 2026, with shares trading higher.

2026-08-17 23:36; UTC

Event

Pfizer Inc shares are lower in after-market hours following the announcement of Xtandi's new indication for prostate cancer treatment. The broader market also declined.

2026-08-14 23:51; UTC

Pfizer Inc. shares are higher in after-market hours amid broader economic concerns following a reported decline in U.S. retail sales for July.

2026-08-13 23:16; UTC

Pfizer Inc shares are lower in after-market hours following a decline from earlier gains. No specific news was identified to explain the movement.

2026-08-12 23:02; UTC

Social Media

News

Pfizer shares rose after Chairman Albert Bourla bought 38,000 shares at $26.34, totaling about $1 million, signaling confidence in the company's prospects.

2026-08-11 19:26; UTC

News

Pfizer Inc. shares are lower amid a $44 million settlement over its Chantix drug, which allegedly contained a cancer-linked substance.

2026-08-10 23:01; UTC

Pfizer Inc. shares are lower in after-market hours, continuing a decline since Monday's close amid rising Treasury yields and inflation concerns.

2026-08-08 00:02; UTC

Pfizer Inc shares are lower in after-market hours with no specific news identified. Broader market concerns about interest rate hikes continue to influence sentiment.

2026-08-07 23:01; UTC

Pfizer Inc shares are lower in after-market hours, reaching a session low earlier. No specific news was identified to explain the decline.

2026-08-06 23:51; UTC

Pfizer Inc shares are lower in after-market hours. The decline follows increased crude oil prices and a strengthening U.S. dollar, contributing to market volatility.

2026-08-05 23:02; UTC

Pfizer Inc shares are modestly higher in after-market hours, reaching a session high before pulling back slightly. No specific news was identified for the movement.

2026-08-04 23:21; UTC

Pfizer Inc shares are lower in after-market hours, with no specific news identified for the decline. Broader market sentiment remains positive amid falling crude oil prices.

2026-08-03 23:46; UTC

Social Media

Pfizer Inc shares are higher in after-market trading ahead of earnings. The stock remains above its 20-day moving average, reflecting positive market sentiment.

2026-07-31 23:06; UTC

Pfizer Inc shares are higher in after-market hours, reflecting slight gains since Friday's close. The stock remains near the upper end of its one-month range.

2026-07-30 23:26; UTC

Event

Pfizer shares are higher in after-market trading following Phase 3 trial results for LITFULO in nonsegmental vitiligo, despite three prior sessions of lower closes.

2026-07-29 23:16; UTC

News

Pfizer and BioNTech received European Commission approval for their XFG-adapted COVID-19 vaccine, valid across all EU member states. Shares are trading roughly flat after-market.

2026-07-28 23:26; UTC

Pfizer Inc shares are lower in after-market hours, reversing an earlier gain. The stock remains above its 20-day moving average.

2026-07-27 18:56; UTC

Pfizer Inc is trading higher, driven by gains in the Pharmaceuticals sub-sector. Shares pulled back earlier in the session from a session high.

2026-07-24 18:06; UTC

Pfizer Inc. shares are lower today, reflecting broader market trends. Earlier, shares fell significantly before partially recovering amid declining crude oil prices.

2026-07-23 09:41; UTC

News

Pfizer Inc. shares are higher in pre-market trading following FDA acceptance of a Priority Review for TALZENNA in combination with XTANDI for prostate cancer.

2026-07-22 23:02; UTC

News

Pfizer Inc. shares are higher in after-market hours following the FDA's acceptance of a Priority Review for TALZENNA and XTANDI in prostate cancer treatment.

2026-07-21 23:11; UTC

News

Pfizer Inc. options trading showed light volume, with calls outpacing puts and a put/call ratio of 0.56. Shares were little changed in after-market hours.

2026-07-20 23:16; UTC

Pfizer Inc shares are higher in after-market trading, maintaining above their 20-day moving average despite broader market pressures from rising treasury yields.

Akcijų palyginimas

Kainos pokytis

Pfizer Prognozė

Kainos tikslas

By TipRanks

6.1% į viršų

12 mėnesių prognozė

Vidutinis 28.51 USD 6.1%

Aukščiausias 35.75 USD

Žemiausias 25 USD

Remiantis 21 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Pfizer kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

21 ratings

Pirkti

Laikyti

Parduoti

Remiantis 21 analitikų, pateikusių Pfizer akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

128 / 340 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.